The estimated Net Worth of Alison Moore is at least $7.46 Milione dollars as of 15 March 2022. Alison Moore owns over 8,698 units of Allogene Therapeutics Inc stock worth over $350,451 and over the last 6 years he sold ALLO stock worth over $3,983,917. In addition, he makes $3,127,980 as Chief Technical Officer at Allogene Therapeutics Inc.
Alison has made over 11 trades of the Allogene Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 8,698 units of ALLO stock worth $66,366 on 15 March 2022.
The largest trade he's ever made was exercising 48,828 units of Allogene Therapeutics Inc stock on 3 June 2019 worth over $110,840. On average, Alison trades about 15,899 units every 46 days since 2019. As of 15 March 2022 he still owns at least 120,430 units of Allogene Therapeutics Inc stock.
You can see the complete history of Alison Moore stock trades at the bottom of the page.
Dr. Alison Moore Ph.D. serves as Chief Technical Officer of the Company. Prior to joining us, she most recently served as Senior Vice President, Process Development at Amgen Inc. from January 2013 until June 2018. Dr. Moore has previously held senior roles at Amgen in Operations Technology from January 2013 until August 2014, Process and Product engineering from January 2011 until January 2013, and Corporate Manufacturing from August 2008 until December 2010. Prior to these positions, she was Vice President, Site Operations at Amgen’s Fremont, California, manufacturing facility, from March 2006 until August of 2008. Before joining Amgen, from 2005 to 2006, Dr. Moore was a Director in Chemistry, Manufacturing and Controls, and Regulatory Affairs at Genentech, Inc. Prior to Genentech, she was a Postdoctoral Research Fellow at the Medical University of Lübeck, Germany. Dr. Moore holds both a bachelor’s degree in Pharmacology with Honors and a Ph.D. in Cell Biology from Manchester University, England.
As the Chief Technical Officer of Allogene Therapeutics Inc, the total compensation of Alison Moore at Allogene Therapeutics Inc is $3,127,980. There are 4 executives at Allogene Therapeutics Inc getting paid more, with David Chang having the highest compensation of $11,192,100.
Alison Moore is 53, he's been the Chief Technical Officer of Allogene Therapeutics Inc since 2018. There are 12 older and 8 younger executives at Allogene Therapeutics Inc. The oldest executive at Allogene Therapeutics Inc is David Bonderman, 77, who is the Lead Independent Director.
Alison's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun e Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
Allogene Therapeutics Inc executives and other stock owners filed with the SEC include: